<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00183742</url>
  </required_header>
  <id_info>
    <org_study_id>0C-00-6</org_study_id>
    <nct_id>NCT00183742</nct_id>
  </id_info>
  <brief_title>Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)</brief_title>
  <official_title>Phase I Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <brief_summary>
    <textblock>
      This study is for patients with advanced cancer that has failed treatment with conventional&#xD;
      therapy or for which no standard treatment exists. The purpose of this study is to determine&#xD;
      the highest dose that can be given of 2 chemotherapy drugs, docetaxel (also called Taxotere)&#xD;
      and liposomal doxorubicin (also called Doxil), when given together and to determine the side&#xD;
      effects of this combination. Both Taxotere and Doxil are chemotherapy drugs that can decrease&#xD;
      the size of several different tumors. Taxotere is approved by the Food and Drug&#xD;
      Administration (FDA) for the treatment of breast and lung cancers, and Doxil is approved for&#xD;
      the treatment of ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) of liposomal doxorubicin (Doxil) administered every 4 weeks or every 2 weeks in combination with docetaxel (Taxotere) administered on a weekly schedule</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To establish the toxicity profile of this combination</measure>
  </primary_outcome>
  <enrollment>35</enrollment>
  <condition>Cancer</condition>
  <condition>Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal doxorubicin and docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological proof of advanced or recurrent solid tumor which has failed prior&#xD;
             therapy, or for which no effective therapy is available.&#xD;
&#xD;
          -  Ovarian cancer patients (or primary peritoneal carcinoma) whose only manifestation of&#xD;
             disease is an elevated cancer antigen (CA) 125 of &gt; 100 are eligible.&#xD;
&#xD;
          -  SWOG performance status 0-2.&#xD;
&#xD;
          -  Absolute granulocyte count (AGC) greater than or equal to 1.5; platelets greater than&#xD;
             or equal to 100,000.&#xD;
&#xD;
          -  Total bilirubin less than or equal to the upper limit of normal (ULN).&#xD;
&#xD;
          -  Transaminases (SGOT and/or SGPT) may be up to 2.5 x institutional upper limit of&#xD;
             normal (ULN) if alkaline phosphatase is &lt;= ULN, or alkaline phosphatase may be up to 4&#xD;
             x ULN if transaminases are &lt;= ULN. However, patients who have both transaminase&#xD;
             elevation &gt; 1.5 x ULN and alkaline phosphatase &gt; 2.5 x ULN are not eligible for this&#xD;
             study (due to decreased clearance of docetaxel and increased risk of toxicity).&#xD;
&#xD;
          -  Age greater than or equal to 18 years.&#xD;
&#xD;
          -  Fully recovered from acute toxicities from chemotherapy, radiation, or surgery.&#xD;
&#xD;
          -  Negative serum pregnancy test, if patient is female, still fertile, and sexually&#xD;
             active.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with Doxil or weekly docetaxel. Prior docetaxel administered every 3&#xD;
             weeks is allowed.&#xD;
&#xD;
          -  Evidence of moderate peripheral neuropathy greater than or equal to grade 2.&#xD;
&#xD;
          -  Medical, social, or psychological factors interfering with compliance.&#xD;
&#xD;
          -  Known history of cardiac disease (congestive heart failure, coronary artery disease)&#xD;
             that would preclude treatment with Doxil in the opinion of the investigator.&#xD;
&#xD;
          -  Cardiac ejection fraction &lt; 50%&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Syma Iqbal, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>U.S.C./Norris Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.S.C./Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>May 20, 2014</last_update_submitted>
  <last_update_submitted_qc>May 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Phase I</keyword>
  <keyword>Phase one</keyword>
  <keyword>Solid tumor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

